title: Audit: the use of radiotherapy for NSCLC in the UK.
abstract: A questionnaire on the management of NSCLC was sent to all clinical oncologists in the UK. Responses were received from 121 individuals with at least one representative response from each of 54 British radiotherapy units. Results were then discussed at an open meeting attended by a cross section of clinical oncologists; a synopsis of responses to the questionnaire and discussion at this meeting is contained in this report. A majority of respondents estimated treatment of NSCLC to make up 10%-25% of their work-load. Radical and palliative treatments could be clearly distinguished, and aims of treatment, selection criteria and radiotherapy schedules were consistent with recommendations in the published literature. More than 90% of treatments were with palliative rather than radical intent. Radical treatment schedules could be divided according to dose (< 50 Gy, 50-55 Gy and >55 Gy), number of fractions (< 20, 20, > 20 fractions), overall time < 4/52, 4/52, > 4/52), dose per fraction (> 2.75 Gy, 2.1-2.75 Gy, < or = 2 Gy) and target volume (tumour alone, tumour and hilar nodes, or tumour, hilar and mediastinal nodes). Divided thus, radical techniques fell into three broad groups, each of the three techniques supported by a body of literature. Choice of schedule could be related to a heterogeneous referral pattern and unresolved controversies, identified as debate on the value of treating mediastinal lymphadenopathy with high dose radiation, the value of 'subradical doses' of radiation for microscopic disease, and the relative importance of volume treated, total dose, dose per fraction and overall treatment time in achieving an optimal therapeutic ratio.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Audit Working Party on behalf of the Faculty of Oncology, Royal College of Radiologists, London, UK.
authors.forename: E J
authors.initials: EJ
authors.lastname: Maher
authors.forename: A
authors.initials: A
authors.lastname: Timothy
authors.forename: C J
authors.initials: CJ
authors.lastname: Squire
authors.forename: A
authors.initials: A
authors.lastname: Goodman
authors.forename: S J
authors.initials: SJ
authors.lastname: Karp
authors.forename: C H
authors.initials: CH
authors.lastname: Paine
authors.forename: R
authors.initials: R
authors.lastname: Ryall
authors.forename: G
authors.initials: G
authors.lastname: Read
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D003625:Data Collection; D006801:Humans; D008175:Lung Neoplasms / Q000532:radiotherapy*; D008722:Methods; D010166:Palliative Care; D011879:Radiotherapy Dosage; D006113:United Kingdom